{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-184757","form_type":"8-K","ticker":"VRDN","cik":"0001590750","company_name":"Viridian Therapeutics, Inc.\\DE","filed_at":"2023-07-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.462428+00:00","generated_at":"2026-06-13T10:35:14.014363+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Viridian announces positive Phase 1/2 data for VRDN-001 in chronic TED; THRIVE trial amended","bullets":["VRDN-001 showed mean proptosis reduction of 1.6 mm (combined doses) at week 6; proptosis responder rate 42%.","No serious adverse events, hearing impairment, or hyperglycemia reported in chronic TED patients.","THRIVE Phase 3 trial amended to 5-dose regimen; topline results expected mid-2024.","THRIVE-2 Phase 3 in chronic TED to start Q3 2023; topline results expected by year-end 2024.","IND filed for VRDN-003 and VRDN-001 SC; lead SC candidate selection expected by year-end 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-184757","json":"https://secwatch.observer/filing/0001193125-23-184757.json","markdown":"https://secwatch.observer/filing/0001193125-23-184757.md","text":"https://secwatch.observer/filing/0001193125-23-184757.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1590750/000119312523184757/0001193125-23-184757-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1590750/000119312523184757/d440197d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T10:35:14.014363+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}